<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01530490</url>
  </required_header>
  <id_info>
    <org_study_id>CEIC0754</org_study_id>
    <nct_id>NCT01530490</nct_id>
  </id_info>
  <brief_title>Cabergoline and Hydroxyethyl Starch in Ovarian Hyperstimulation Syndrome Prevention</brief_title>
  <official_title>Prevention of Ovarian Hyperstimulation Syndrome in GnRH Agonist IVF Cycles: Randomized Study Comparing Hydroxyethyl Starch Versus Cabergoline and Hydroxyethyl Starch</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Cruces</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Cruces</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether, in GnRH agonist in vitro fertilization (IVF)
      cycles, where there is a risk of ovarian hyperstimulation syndrome (OHSS), the addition of
      cabergoline to the hydroxyethyl starch infusion could decrease OHSS incidence and severity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women undergoing IVF cycles with GnRH agonist protocols, at risk of OHSS (more than 20
      follicles observed larger than 12 mm in diameter and/or estradiol levels of 3000-5000 pg/mL).

      Slow infusion of 500 ml of 6% HES during follicular aspiration alone or combined with 0.5 mg
      cabergoline administration for 8 days, starting on the day of hCG administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>risk of ovarian hyperstimulation syndrome</measure>
    <time_frame>12 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pregnancy rate</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Complications Associated With Artificial Fertilization</condition>
  <condition>Disorder of Endocrine Ovary</condition>
  <arm_group>
    <arm_group_label>Hemoes</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cabergoline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cabergoline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabergoline and Hydroxyethyl Starch</intervention_name>
    <description>0.5mg</description>
    <arm_group_label>Cabergoline</arm_group_label>
    <other_name>Dostinex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxyethyl Starch</intervention_name>
    <description>0.5 mg cabergoline administration 8 days</description>
    <arm_group_label>Cabergoline</arm_group_label>
    <other_name>Hemoes</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  to be at risk of OHSS were invited to participate in the study

        Exclusion Criteria:

          -  age &gt; 40 years
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Matorras, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Cruces</affiliation>
  </overall_official>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2012</study_first_submitted>
  <study_first_submitted_qc>February 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2012</study_first_posted>
  <last_update_submitted>February 9, 2012</last_update_submitted>
  <last_update_submitted_qc>February 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Cruces</investigator_affiliation>
    <investigator_full_name>Roberto Matorras</investigator_full_name>
    <investigator_title>Head of reproduction Unit</investigator_title>
  </responsible_party>
  <keyword>IVF</keyword>
  <keyword>ovarian hyperstimulation syndrome</keyword>
  <keyword>cabergoline</keyword>
  <keyword>hydroxyethyl starch</keyword>
  <keyword>prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
    <mesh_term>Ovarian Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cabergoline</mesh_term>
    <mesh_term>Hydroxyethyl Starch Derivatives</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

